VEGF‐A induces its negative regulator, soluble form of VEGFR‐1, by modulating its alternative splicing

[1]  L. Claesson‐Welsh,et al.  Signal transduction by vascular endothelial growth factor receptors. , 2011, The Biochemical journal.

[2]  Ji Li,et al.  Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer , 2011, Expert review of anticancer therapy.

[3]  Chiun Hsu,et al.  Serum Vascular Endothelial Growth Factor/Soluble Vascular Endothelial Growth Factor Receptor 1 Ratio Is an Independent Prognostic Marker in Pancreatic Cancer , 2008, Pancreas.

[4]  S. Yagel,et al.  A Novel Human-Specific Soluble Vascular Endothelial Growth Factor Receptor 1: Cell Type-Specific Splicing and Implications to Vascular Endothelial Growth Factor Homeostasis and Preeclampsia , 2008, Circulation research.

[5]  Kang Z. Liu,et al.  Intronic polyadenylation signal sequences and alternate splicing generate human soluble Fltl variants and regulate the abundance of soluble Flt1 in the placenta , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  H. Kim,et al.  Copyright � The Korean Academy of Medical Sciences The Levels of Circulating Vascular Endothelial Growth Factor and , 2006 .

[7]  D. Morton,et al.  The Wnt antagonist sFRP1 is downregulated in premalignant large bowel adenomas , 2006, British Journal of Cancer.

[8]  A. Muñoz,et al.  The Wnt antagonist DICKKOPF-1 gene is a downstream target of β-catenin/TCF and is downregulated in human colon cancer , 2005, Oncogene.

[9]  R. Gaiser,et al.  Circulating Angiogenic Factors and the Risk of Preeclampsia , 2005 .

[10]  ShakilAhmad,et al.  Elevated Placental Soluble Vascular Endothelial Growth Factor Receptor-1 Inhibits Angiogenesis in Preeclampsia , 2004 .

[11]  M. Abe,et al.  Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. , 2004, The Journal of clinical investigation.

[12]  W. Huckle,et al.  Post‐transcriptional control of expression of sFlt‐1, an endogenous inhibitor of vascular endothelial growth factor , 2004, Journal of cellular biochemistry.

[13]  KojiMaemura,et al.  Endothelial PAS Domain Protein 1 Gene Promotes Angiogenesis Through the Transactivation of Both Vascular Endothelial Growth Factor and Its Receptor, Flt-1 , 2004 .

[14]  Yoshiaki Kawano,et al.  Secreted antagonists of the Wnt signalling pathway , 2003, Journal of Cell Science.

[15]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[16]  M. Westphal,et al.  Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .

[18]  H. Hamada,et al.  Gene Therapy for Pancreatic Cancer Using an Adenovirus Vector Encoding Soluble flt-1 Vascular Endothelial Growth Factor Receptor , 2002, Pancreas.

[19]  Y. Taketani,et al.  Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. , 2002, Cancer research.

[20]  Masakazu,et al.  Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor‐1 relationship in breast cancer , 2002, International journal of cancer.

[21]  S. Kliche,et al.  VEGF Receptor Signaling and Endothelial Function , 2001, IUBMB life.

[22]  L. Claesson-Welsh.  Signal transduction by vascular endothelial growth factor receptors. , 2001, Biochemical Society transactions.

[23]  M. Shibuya.  Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. , 2001, Cell structure and function.

[24]  A. Larue,et al.  VEGF regulates cell behavior during vasculogenesis. , 2000, Developmental biology.

[25]  K. Alitalo,et al.  Amniotic Fluid–Soluble Vascular Endothelial Growth Factor Receptor‐1 in Preeclampsia , 2000, Obstetrics and gynecology.

[26]  R. Jaffe,et al.  Importance of angiogenesis in reproductive physiology. , 2000, Seminars in perinatology.

[27]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  G. Martiny-Baron,et al.  The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities , 1998, Cancer and Metastasis Reviews.

[29]  J. Waltenberger,et al.  Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. , 1998, Experimental cell research.

[30]  K. Plate,et al.  Angiogenesis in Embryos and Ischemic Diseases , 1997, Thrombosis and Haemostasis.

[31]  R. Kendall,et al.  Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.

[32]  J. Winer,et al.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.

[33]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.

[34]  M. Persico.  Placenta Growth Factor , 2001 .

[35]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.